| Quarter | Call date | Disclosure | Financial quality | Kept | Missed | |
|---|---|---|---|---|---|---|
| Q3'26 | October 21, 2026 | 8/12 | 1 high, 4 medium, 2 low flags | 2 | 1 | Call sheet → |
| Q2'26 | July 16, 2026 | 4/12 | 2 high, 3 medium, 1 low flags | 2 | 1 | Call sheet → |
| Q1'26 | April 16, 2026 | 9/12 | 3 medium, 3 low flags | 4 | 0 | Call sheet → |
| Q4'25 | January 22, 2026 | 9/12 | 2 medium, 4 low flags | 5 | 1 | Call sheet → |
| Marked | Status | Promise |
|---|---|---|
| Q3'26 | Pending | 7% sustainable long-term total company growth target reaffirmed Not reaffirmed with the same confidence this quarter; management explicitly adopted a more conservative framing ahead of formal 2027 guidance in January. |
| Q3'26 | Pending | US Type 2 non-insulin CGM reimbursement expansion could happen 'in the fall' No CMS decision disclosed this quarter; management now explicitly says it is not factored into forecasts, suggesting the fall timeline is slipping. |
| Q3'26 | Pending | Potential to get new LAA device (Amulet 360) FDA approved by year end Only CE Mark was obtained this quarter (EU), not FDA approval; U.S. approval timeline remains open. |
| Q3'26 | Pending | Expect Structural Heart to return to mid-to-high single digit growth by year end Segment was not mentioned at all this quarter; unverified whether the turnaround is on track, delayed, or quietly abandoned from the narrative. |
| Q3'26 | Pending | Expect global EP growth to accelerate in H2 and outperform the market Q3 EP growth was strong but Q4 outlook was cut ~5 points due to an LAA-related order slowdown management did not anticipate. |
| Q3'26 | Missed | CGM market described as plateauing around 8%-9% growth absent reimbursement expansion Actual trajectory cut further to low-to-mid single digits this quarter, worse than the 8-9% characterization given last quarter. |
| Q3'26 | Delivered | Expect to transition Bolt from limited to full market release in Q3 Confirmed transition to full U.S. market release occurred mid-August, within the quarter. |
| Q3'26 | Delivered | Q3 adjusted EPS guidance of $1.38-$1.46 Actual $1.42 landed within the range and matched consensus. |
| Q3'26 | Pending | Raised FY2026 adjusted EPS guidance to $5.45-$5.60 Not restated or reconciled on this call; unverified whether this range still holds given the top-line cut. |
| Q3'26 | Pending | Reaffirmed full-year comparable sales guidance of 6.5%-7.5% FY2026 has not closed; guidance was walked down to ~6% implied this quarter, a revision not a miss by the letter of the rules, but a clear credibility hit given it followed a Q3 beat. |
| Q2'26 | Pending | Cancer diagnostics H2 higher than H1 Maintained 13% in Q2, needs acceleration to deliver |
| Q2'26 | Exceeded | Maintain high single digit EPD growth Delivered 9% growth, at high end of range |
| Q2'26 | Pending | Core Lab growth higher in H2 vs H1 Q2 was flat at 3% growth, needs significant H2 acceleration |
| Q2'26 | Delivered | EP growth to accelerate with PFA launches 20% growth in Europe, acceleration visible |
| Q2'26 | Pending | Nutrition growth improving over the course of the year Q2 showed $125M sequential improvement, on track but not proven |
| Q2'26 | Missed | CGM to return to double-digit growth in Q2 Grew 9.5% vs promised double digits, blamed on tender delay |
| Q1'26 | Delivered | Exact Sciences acquisition close by Q1 2026 Closed March 23, 2026 as expected |
| Q1'26 | Delivered | EPS growth of 10% for full year 2026 Maintained 10% EPS growth guidance despite Exact dilution |
| Q1'26 | Exceeded | Core Lab Diagnostics acceleration through 2026 Sequential growth achieved in Q1, ahead of expectations |
| Q1'26 | Delivered | Volt PFA catheter US launch in Q1 FDA approval and limited market release achieved in Q1 |
| Q1'26 | Pending | Double-digit CGM growth resumption in Q2 Ford committed 'we expect CGM to return to double-digit growth' in Q2 |
| Q1'26 | Pending | Nutrition return to growth in second half of 2026 Still on track but language softened to 'early signs encouraging' vs confident commitment |
| Q4'25 | Delivered | Aveir dual chamber penetration acceleration CRM growth maintained at 12%, dual chamber penetration sub-10% with room to grow |
| Q4'25 | Exceeded | Continuing margin expansion trajectory Operating margin expanded 150 bps vs 40 bps prior quarter |
| Q4'25 | Delivered | Sustaining high single-digit growth in large portions of portfolio Medical devices, EPD maintaining growth rates despite some moderation |
| Q4'25 | Pending | Diagnostics headwinds from China VBP and COVID to ease Says will lap in Q4 2025 and 2026, but not yet visible in Q4 results |
| Q4'25 | Delivered | Volt PFA catheter launch in US next year Received FDA approval in December, began limited market release |
| Q4'25 | Delivered | Double-digit EPS growth target Guided to 10% EPS growth at midpoint, consistent with original commitment |
| Q4'25 | Missed | Comfortable with 7.5% revenue growth consensus for 2026 Guided to 6.5%-7.5% range with 7% midpoint, citing nutrition headwinds |
Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.
Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.